ConductScience.org, home

Paper19620385

Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.

Wang DD and 4 others. J Clin Pharmacol, 2009. Cited by 153 papers, by iCite.

Cite this record

ConductScience Library. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. Papers, record 19620385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19620385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
PubMed
Journal
J Clin Pharmacol
PubMed
Year
2009
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
153
iCite
Relative citation ratio, by iCite
3.62
iCite
Revised in PubMed
2009-08-31
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang DDDiane D
2Zhang SShuzhong
3Zhao HHong
4Men AYAngela Y
5Parivar KKourosh

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Models, BiologicalMajor topic
Adult
Body Surface Area
Body Weight
Clinical Trials as Topic
Computer Simulation
Dose-Response Relationship, Drug
Humans

Source PubMed

Download CSV of topics

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04062708CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerBackgroundClinicalTrials.gov
NCT04441138Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCBackgroundClinicalTrials.gov
NCT04765709Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCBackgroundClinicalTrials.gov
NCT05568212Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabBackgroundClinicalTrials.gov
NCT07146230The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2BackgroundClinicalTrials.gov

Download CSV of trials

Cited by93

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.

PMIDTitleJournalYearIn PapersSource
42742477Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.J Clin Pharmacol2026https://conductscience.org/library/papers/42742477PubMed
42671472Body weight predicts denosumab pharmacodynamic duration: a real-world longitudinal cohort study.Osteoporos Int2026https://conductscience.org/library/papers/42671472PubMed
42469164Denecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4.Blood Adv2026https://conductscience.org/library/papers/42469164PubMed
41824265Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification.Paediatr Drugs2026https://conductscience.org/library/papers/41824265PubMed
41466592Optimizing Body Size-Based Dosing Approaches for Antibody-Drug Conjugates.Clin Pharmacol Ther2026https://conductscience.org/library/papers/41466592PubMed
41321671Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.Drug Des Devel Ther2025https://conductscience.org/library/papers/41321671PubMed
41310951Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All.Arthritis Rheumatol2026https://conductscience.org/library/papers/41310951PubMed
40920298Targeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.BioDrugs2025https://conductscience.org/library/papers/40920298PubMed
40830740Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach.Target Oncol2025https://conductscience.org/library/papers/40830740PubMed
40817431Re-Evaluation of Fixed Dosing Versus Body Size-Based Dosing Approaches for Large Molecule Therapeutics in Adults.Clin Pharmacol Ther2025https://conductscience.org/library/papers/40817431PubMed
40686031Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling of Serum M-Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma.Clin Transl Sci2025https://conductscience.org/library/papers/40686031PubMed
40667684Donanemab exposure-response in early symptomatic Alzheimer's disease.Alzheimers Dement2025https://conductscience.org/library/papers/40667684PubMed
40458046Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.J Antimicrob Chemother2025https://conductscience.org/library/papers/40458046PubMed
40427101Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?Cancers (Basel)2025https://conductscience.org/library/papers/40427101PubMed
40316348A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.BMJ Open2025https://conductscience.org/library/papers/40316348PubMed
40308078Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure-Response Analyses.Clin Pharmacol Ther2025https://conductscience.org/library/papers/40308078PubMed
40000533Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma.Target Oncol2025https://conductscience.org/library/papers/40000533PubMed
39849218Pharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity.Pharm Res2025https://conductscience.org/library/papers/39849218PubMed
39375952Population pharmacokinetic model of ABL001/CTX-009 (anti-VEGF/DLL4) in adult cancer patients with solid tumor.Cancer Sci2024https://conductscience.org/library/papers/39375952PubMed
38711252Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer.CPT Pharmacometrics Syst Pharmacol2024https://conductscience.org/library/papers/38711252PubMed

See all 93 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19620385

GET https://conductscience.org/api/papers/v1/19620385/cited_by?page=2